Pharma Sector Developments: Zydus, Jagsonpal, and Biocon Make Strategic Moves

Zydus Lifesciences has forged a pivotal partnership with Netherlands-based Synthon BV to launch a generic multiple sclerosis treatment in the US market. The exclusive licensing deal for Ozanimod capsules—a ZEPOSIA alternative—marks a strategic expansion for Zydus, leveraging Synthon’s pending FDA application.

Jagsonpal Pharma signals growth ambitions with the appointment of industry veteran Amrut Medhekar as CEO. His tenure at Akums Drugs and Wockhardt positions him to drive operational efficiency and innovation at the company.

Biocon Biologics faces regulatory scrutiny after the USFDA issued five observations following a routine inspection of its Bengaluru facility. The evaluation covered drug substance manufacturing and quality control units, underscoring ongoing compliance challenges in the sector.